Precision Vaccinations | April 14, 2020
Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mechanisms that offer fair access for people in all countries.’ This new collaboration marks a significant milestone in Sanofi’s and GSK’s ongoing contributions to help fight COVID-19. The companies have entered into a Material Transfer Agreement to enable them to start working together immediately. Definitive terms of the collaboration are expected to be finalized over the next few weeks.
Read More
HITInfrastructure | October 10, 2019
IU is employing these technologies to target certain cancers, such as multiple myeloma, triple-negative breast cancer, and pediatric sarcomas, and chronic diseases, such as diabetes and Alzheimer’s, explained Peter Embi, MD, president and CEO of Regenstrief Institute, which is a medical research organization affiliated with IU and Purdue University. IU decided to partner with LifeOmic, which provides a secure cloud service for the long-term storage, retrieval, analysis, and clinical use of medical research data. IU has a 1.5 percent ownership stake in LifeOmic, which was founded by Don Brown, an IU alumnus. In addition, IU and other universities, through their Indiana Clinical Translational Sciences Institute (CTSI), are working with LifeOmic to provide the LIFE Extend app to enable Indiana residents to live a healthy lifestyle. CTSI is a research partnership among IU, Purdue University, and the University of Notre Dame. The LIFE Extend app includes the option for users to participate in the All IN for Health program, which links Indiana residents with opportunities to improve their health and participate in research and clinical studies. Indiana CTSI and LifeOmic have set a goal of engaging more than 100,000 residents in the All IN for Health program.
Read More
Precision Therapeutics Inc. | April 11, 2019
PITTSBURGH, April 11, 2019 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT) (“Precision” or “the Company”) today announced that its wholly-owned subsidiary, Helomics® Corporation (Helomics), which provides personalized medicine solutions and boutique CRO services for clients in the pharmaceutical, diagnostic, and biotechnology industries, and SpeciCare, an innovative Georgia-based company connecting cancer patients to new treatment options only available through storing the patient’s live tumor tissue, have signed an agreement for Helomics to provide CRO services and its D-CHIP artificial intelligence (AI) platform for a functional precision medicine study sponsored by SpeciCare. “SpeciCare is at the forefront of a renewed interest in functional precision medicine, which has been core to our personalized oncology approach for many years. We are excited to work with SpeciCare on their PIONEER initiative study, which will utilize Helomics’ core functional precision medicine technology of live tumor drug profiling assays (TruTumor™) and genomic profiling coupled with our AI-driven bioinformatics platform, D-CHIP,” commented Gerald J. Vardzel Jr., president of Helomics. “This collaboration further demonstrates the value of our CRO services and D-CHIP platform, both to generate revenue, and advance personalized medicine to improve patient treatment and outcomes.” Functional precision medicine goes beyond pure genomics to test live tumor tissue from the patient with a variety of approaches that interrogate how the tumor behaves, such as when challenged with potential therapies. Traditional genomics-only approaches often do not provide clinically actionable results outside of a handful of approved genomic biomarkers and associated drugs, limiting clinicians’ options for individualizing therapy.
Read More